Biocept Inc. WKN: A2QEQE ISIN: US09072V5012 Forum: Aktien User: Auweia

Dafür aber im Dezember umso kräftiger :( Wie sieht ihr denn diese Firma, wird's was draus? Die Analystenbewertungen in TR jedenfalls (taugen aber oft nix!) liegen um ein Vielfaches über den aktuellen Kurs.

Biocept wird strategische Alternativen prüfen und einen Restrukturierungsplan umsetzen Untersuchung strategischer Alternativen; Umsetzung des Umstrukturierungsplans, Abbau von 35 % der Belegschaft 🥳

🎈

👍

🍷

danke dir!

Aus Q3 Report.

Biocept reported cash as of September 30, 2022 of $18.0 million, compared with $28.9 million as of December 31, 2021.

weißt du evtl. was die noch cash haben?

sieht so aus ... wobei ich nicht weiß, wie der Markt diesen Sachverhalt wertet: ... has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. ... Nachbörslich jedenfalls eher positiv als negativ ... aber das kann man schlecht werten.

Zahlen da. Übel...

SAN DIEGO--(BUSINESS WIRE)--Nov. 16, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic pilot study to evaluate the cerebrospinal fluid tumor and immune cell microenvironment in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. The study is designed to identify biomarkers associated with central nervous system (CNS) metastasis, enabling a better understanding of treatment response, prognosis, and treatment resistance that may improve the management of CNS disease in patients with metastatic breast cancer.

SAN DIEGO--(BUSINESS WIRE)--Oct. 17, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, Biocept’s CNSide is a proprietary CSF assay designed to better detect and inform treatment decisions for patients with metastatic cancers involving the central nervous system (CNS).

https://www.businesswire.com/news/home/20220913006159/en/Global-Liquid-Biopsy-Market-Analysis-Report-2022-A-10.4-Billion-Market-by-2027---Opportunities-in-Reference-Laboratories-Hospitals-and-Physician-Laboratories-and-Academic-and-Research-Centers---ResearchAndMarkets.com

https://www.openpr.com/news/2749426/cell-free-dna-cf-dna-testing-market-size-soaring-at-high-cagr